Publication
Title
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
Author
Abstract
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
Language
English
Source (journal)
Cell. - Cambridge, Mass.
Publication
Cambridge, Mass. : 2010
ISSN
0092-8674
DOI
10.1016/J.CELL.2010.02.039
Volume/pages
141 :1 (2010) , p. 178-190
ISI
000276211100022
Pubmed ID
20371353
Full text (Publisher's DOI)
UAntwerpen
Research group
Publication type
Subject
External links
Web of Science
Record
Identifier
Creation 15.02.2024
Last edited 16.02.2024
To cite this reference